Intravacc, a contract development and manufacturing organisation of viral and bacterial vaccines, has named Prof Dr Virgil Schijns as its new chief scientific officer, it was reported on Thursday.

In the new role, Prof Schijns will be responsible for the scientific and clinical strategy, including scientific and clinical affairs. Dr Schijns has more than 25 years of scientific, clinical and vaccine development experience in oncology and infectious diseases. He was named special professor in Immunology and Virology at North Carolina State University in 2022 and guest professor of Immune Intervention at Wageningen University, The Netherlands, Department Cell Biology & Immunology. He has been guest professor at Strathclyde University Glasgow United Kingdom. He also has extensive experience in the Life Science and Biotech sector and was CSO of Epitopoietic Research Corporation SA in Namur, Belgium and, before that, chief technology officer of Crossbeta Biosciences. He was earlier principal immunologist of Nobilon and head of Vaccine Technology and Immunology at Intervet-AKZONOBEL.